Results 291 to 300 of about 384,078 (314)

Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations

Clinical Immunology, 2004
Evidence supports the association between infectious agents, antiphospholipid syndrome (APS), and the presence of antiphospholipid antibodies and anti-beta2-glycoprotein-I (beta2GPI) antibodies. Several mechanisms have been proposed to explain the role of bacteria/viruses in induction of an autoimmune condition, such as molecular mimicry between ...
Miri Blank, Yehuda Shoenfeld, Yehuda Shoenfeld   +2 more
openaire   +3 more sources

Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?

Lupus, 1995
Anticardiolipin (aCL) and anti-beta2-glycoprotein I(antiβ2GPI) antibodies have been shown in animal models as not cross-reacting antibody populations. This observation prompted us to prove if anti-β2GPI exist in human sera by using a reliable method and then to investigate if these are independent from aCl antibodies. We have developed a new ELISA for
G. Balestrieri, A. Tincani, L. Spatola, F. Allegri, E. Prati, R. Cattaneo, VALESINI, Guido, N. Del Papa, P. Meroni   +8 more
openaire   +4 more sources

Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab

Annals of the Rheumatic Diseases, 2018
The current management of antiphospholipid syndrome (APS) centres on attenuating the procoagulant state while balancing the haemorrhagic risks.1 This approach relies mainly on a thromboprophylaxis strategy rather than targeting pathogenic ...
S. Sciascia, E. Rubini, M. Radin, I. Cecchi, D. Rossi, D. Roccatello   +5 more
semanticscholar   +1 more source

Anticardiolipin Antibody and Anti-beta 2 Glycoprotein I Antibody Assays

2013
Antiphospholipid syndrome (APS) is an autoimmune disease and is a risk factor for a number of clinical manifestations; the classic presentations include fetal death or thrombosis (arterial or venous thromboembolism), in the presence of persistently increased titers of antiphospholipid (aPL) antibodies.
Mark Crowther, Anne Raby, Karen A. Moffat   +2 more
openaire   +2 more sources

Antiphospholipid antibodies: significance of anti-beta-2-glycoprotein i isotypes

Pathology, 2015
Antiphospholipid syndrome (APS) is an autoimmune thrombophilia. It causes significant morbidity and mortality, arising from recurrent arterial and venous thromboses as well as obstetric complications such as pre-eclampsia and recurrent miscarriages.
Anna Brusch, Anna Brusch
openaire   +2 more sources

AB0131 Tissue Beta 2 glycoprotein I in Brain Ischemic Injury

Annals of the Rheumatic Diseases, 2016
Background Thrombosis of arteries in the central nervous system (CNS) represents the most frequent CNS manifestation and the most frequent arterial event in antiphospholipid syndrome (APS). Previous in vivo studies demonstrated that beta2 glycoprotein I (β2GPI) - the main antigenic target for anti-phospholipid antibodies (aPL) - does not localize in ...
Maria Orietta Borghi, Claudia Grossi, Pl Meroni, Carolina Artusi, M.G. De Simoni, Stefano Fumagalli, Francesco Tedesco, Marco Oggioni   +7 more
openaire   +2 more sources

Testing for the antiphospholipid syndrome: importance of IgA anti-beta 2-glycoprotein I

Lupus, 2000
Background: Testing for the antiphospholipid syndrome (APS) using anticardiolipin antibodies (aCL) has been problematic. Titers may fluctuate or even become negative. Anti-beta 2 glycoprotein I assays (ab2-GPI) may be more reliable for diagnosis. Methods: In a prospective, blinded study over a nine-month period we retested all patients seen for ...
T P Greco, T P Greco, J.W. Ijdo, Michael D. Amos, A M Conti-Kelly, J.D. Naranjo   +5 more
openaire   +3 more sources

Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes.

Biochemistry, 1996
beta 2-Glycoprotein I (beta 2GPI) is an essential cofactor for the binding to lipids of anticardiolipin antibodies (ACA), isolated from patients with anti-phospholipid syndrome.
G. Willems, M. P. Janssen, M. Pelsers, P. Comfurius, M. Galli, R. Zwaal, E. Bevers   +6 more
semanticscholar   +1 more source

Anti-cardiolipin and anti-beta 2-glycoprotein I antibodies in celiac disease

Pathologie Biologie, 2012
To determine the frequency of anti-cardiolipin (aCL) and anti-β2-glycoprotein I antibodies (aβ2GPI) in celiac disease (CD) patients.Sixty-three untreated CD patients and 40 healthy blood donors (HBD) were studied. IgG, IgA and IgM aCL and aβ2GPI were detected by Elisa.The frequency of antiphospholipid antibodies (aPL) (aCL and/or aβ2GPI) was ...
Y. Thabet, W. Manoubia, A. Achour, Ibtissem Ghedira, W. Sakly, Amani Mankaï   +5 more
openaire   +3 more sources

Anti-beta 2-glycoprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind to beta 2-glycoprotein I with low affinity: dimerization of beta 2-glycoprotein I induces a significant increase in anti-beta 2-glycoprotein I antibody affinity.

Journal of immunology (Baltimore, Md. : 1950), 1998
"Antiphospholipid" autoantibodies are associated with arterial and venous thrombosis, recurrent fetal loss, and thrombocytopenia. At present, the best-characterized antigenic target for these autoantibodies (or Abs) is the phospholipid-binding protein beta2-glycoprotein I (beta2GPI).
Y, Sheng, D A, Kandiah, S A, Krilis
openaire   +1 more source